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Abstract: The search for new alternatives for the prevention and treatment of cancer is extremely
important to minimize human mortality. Natural products are an alternative to chemical
drugs, since they are a source of many potential compounds with anticancer properties. In the
present study, the (2S)-5,7-dihydroxy-6-prenylflavanone (semi-systematic name), also called
(2S)-5,7-dihydroxy-6-(3-methyl-2-buten-1-yl)-2-phenyl-2,3-dihydro-4H-1-Benzopyran-4-one (CAS
Name registered) (1) was isolated from Eysenhardtia platycarpa leaves. This flavanone 1 was considered
as the lead compound to generate new cytotoxic derivatives 1a, 1b, 1c and 1d. These compounds
1, 1a, 1b, 1c, and 1d were then loaded in nanosized drug delivery systems such as polymeric
nanoparticles (NPs). Small homogeneous spherical shaped NPs were obtained. Cytotoxic activity
of free compounds 1, 1a, 1b, 1c, and 1d and encapsulated in polymeric NPs (NPs1, NPs1a, NPs1b,
NPs1c and NPs1d) were evaluated against the pancreatic cancer cell line MiaPaCa-2. The obtained
results demonstrated that NPs1a and NPs1b exhibited optimal cytotoxicity, and an even higher
improvement of the cytotoxic efficacy was exhibited with the encapsulation of 1a. Based on these
results, NPs1a were proposed as promising anticancer agent candidates.
Keywords: flavanone; Eysenhardtia; cytotoxic activity; MiaPaCa-2
1. Introduction
Flavonoids are low molecular weight polyphenolic compounds derived from secondary
metabolism of plants. The structural substitution in the flavonoid ring system with prenyl groups
increases the lipophilicity and its affinity for biological membranes [1]. Several prenylated flavanones
with antioxidant, anti-inflammatory, hepatoprotective and/or cytotoxic activities have been widely
identified from natural sources [2]. Concretely, flavanones obtained from Fabaceae family have been
reported to be compounds with some functional groups granting them higher biological activity [3],
such as chalcones, isoflavones and flavanones with functionalized groups at specific positions [4], as
Molecules 2017, 22, 1553; doi:10.3390/molecules22091553 www.mdpi.com/journal/molecules
Molecules 2017, 22, 1553 2 of 21
well as flavanones linked to pyran ring [5]. These functional group modifications have been found to
increase their pharmacological effects, mainly the anti-inflammatory and cytotoxic actions [6].
In a previous work the anti-inflammatory, antioxidant and cytotoxic activities of natural
flavanones isolated from the methanolic extract of Eysenhardtia platycarpa leaves have been reported [2].
Flavanones exhibited anti-inflammatory activity in an inflammatory induction model on mouse ear and
cytotoxic activity by the Artemia salina (brine shrimp) method. Different structural modifications such
as esterification (compound 1a), methylation (compound 1b), cyclization (compound 1c) or vinylogous
cyclization (compound 1d) of the isolated flavanone 1 represent a suitable strategy to obtain new
compounds with improved biological efficacy as wells as a strategy to evaluate the influence of the
substitution pattern on the structure–activity relationship.
Among the broad spectrum of biological activities of flavonoids in general and concretely, in
flavonoids with prenylated phenol groups, cytotoxicity is one of the most investigated pharmacological
effects [7]. In this context the search of new or improved anti-cancer molecules is a challenging field
for scientists. The main goal of cancer therapy is to kill the tumor cells, and the initial step in the
evaluation of the potential antitumor efficacy of new bioactive substances is the assessment of their
cytotoxic effect in human cancer cell lines.
The vehiculization of the active substance in an appropriate delivery system (liposomes, solid lipid
nanoparticles, nanoemulsios and polymeric nanoparticles, among others) provides advantages and
therapeutic benefits in term of kinetics release delivery, biodistribution regulation and minimization of
significant side effect. These benefits have been observed in natural flavanones loaded in nanoemulsion
and poly(DL-lactide-co-glycolide acid) (PLGA) nanoparticles (NPs) [8,9].
In this case, PLGA-NPs were considered as suitable delivery systems due to their ability for
enhancing the bioavailability of hydrophobic drugs such as the natural flavanone 1 and derivatives
compounds 1a, 1b, 1c and 1d which possess hydrophobic nature given by their functional groups
based on one of their functional components [10].
Among the wide range of nanosystems for drug delivery, NPs play an important role in the cancer
treatment providing additional advantages over the use of free drugs [11]. Among them, PLGA is
one of the best reported polymers for the elaboration of biomedical NPs due to its biocompatibility.
PLGA is easily metabolized into lactic and glycolic acids and excreted by the body as carbon dioxide
and water [12].
Based on the previous comments and considering the potential cytotoxicity of flavanones isolated
from E. platycarpa leaves: (2S)-5,7-dihydroxy-6-(3-methyl-2-buten-1-yl)-2-phenyl-2,3-dihydro-4H-1-
Benzopyran-4-one (1), as well as derivatives obtained from structural modifications:
(2S)-5,7-bis(acetyloxy)-6-(3-methyl-2-buten-1-yl)-2-phenyl-2,3-dihydro-4H-1-Benzopyran-4-one (1a);
(2S)-5-hydroxy-7-methoxy-6-(3-mehyl-2-buten-1-yl)-2-phenyl-2,3-dihydro-4H-1-Benzopyran-4-one
(1b); (8S)-5-hydroxy-2,2-dimethyl-8-prenyl-3,4,7,8-tetrahydro-2H,6H-Benzo[1,2-b:5,4-b′]dipyran-6-one
(1c); and (8S)-5-hydroxy-2,2-dimethyl-8-phenyl-7,8-dihydro-2H,6H-Benzo[1,2-b:5,4-b′]dipyran-6-one
(1d) (Figure 1) might be considered as optimal candidates for the investigation as anticancer
agents. The main aim of this study was the evaluation of the cytotoxic activity of these flavonoids
compounds 1, 1a, 1b, 1c and 1d free and loaded in effective PLGA-NPs against pancreatic cancer cell
line (MiaPaCa-2).
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Figure 1. Chemical structures of the studied compounds. (2S)-5,7-dihydroxy-6-(3-methyl-2-buten-1- 
yl)-2-phenyl-2,3-dihydro-4H-1-Benzopyran-4-one (1); (2S)-5,7-bis(acetyloxy)-6-(3-methyl-2-buten-1- 
yl)-2-phenyl-2,3-dihydro-4H-1-Benzopyran-4-one (1a); (2S)-5-hydroxy-7-methoxy-6-(3-mehyl-2-buten- 
1-yl)-2-phenyl-2,3-dihydro-4H-1-Benzopyran-4-one (1b); (8S)-5-hydroxy-2,2-dimethyl-8-prenyl-3,4,7,8- 
tetrahydro-2H,6H-Benzo[1,2-b:5,4-b′]dipyran-6-one (1c) and (8S)-5-hydroxy-2,2-dimethyl-8-phenyl-7,8- 
dihydro-2H,6H-Benzo[1,2-b:5,4-b′]dipyran-6-one (1d). 
2. Results and Discussion 
2.1. Chemical Characterization 
The structural elucidation of the flavanone 1 was reported by Ahluwalia et al. [13] and the (2S) 
configuration structure by Narvaez et al. [14]. Flavanone 1 (Figure 1) was obtained (0.329 g) as a 
yellow solid with a melting point of 200–202 °C. It showed a molecular ion of m/z 324 in the mass 
spectrum, in addition to the peaks of typical fragmentations of previously described flavanones [15]. 
The molecular ion also confirmed the molecular formula C20H20O4. The infrared (IR) spectrum 
showed bands for hydroxyl group in 3134 cm−1 and a band in 1634 cm−1 corresponding to a carbonyl 
group. Characterization was also performed by spectroscopic techniques such as: 1H nuclear 
magnetic resonance (NMR), 13C-NMR, correlated spectroscopy (COSY), distortion-less enhancement by 
polarization transfer (DEPT), heteronuclear single quantum correlation spectroscopy (HSQC), 
(heteronuclear multiple bond correlation) HMBC and nuclear overhauser enhancement spectroscopy 
(NOESY). 
2.2. Pharmacomodulation 
Pharmacomodulation is a molecular design strategy in which an already established lead 
compound is modified to improve its pharmacokinetic and/or pharmacodynamics parameters. 
Flavanone 1 (as lead compound) was considered in the present work for the development of new 
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Figure 1. Chemical structures of the studied compounds. (2S)-5,7-dihydroxy-6-(3-methyl-2-buten-
1-yl)-2-phenyl-2,3-dihydro-4H-1-Benzopyran-4-one (1); (2S)-5,7-bis(acetyloxy)-6-(3-methyl-2-buten-1-yl)-
2-phenyl-2,3-dihydro-4H-1-Benzopyran-4-one (1a); (2S)-5-hydroxy-7-methoxy-6-(3-mehyl-2-buten-1-yl)-
2-phenyl-2,3-dihydro-4H-1-Benzopyran-4-one (1b); (8S)-5-hydroxy-2,2-dimethyl-8-prenyl-3,4,7,8-
tetrahydro-2H,6H-Benzo[1,2-b:5,4-b′]dipyran-6-one (1c) and (8S)-5-hydroxy-2,2-dimethyl-8-phenyl-7,8-
dihydro-2H,6H-Benzo[1,2-b:5,4-b′]dipyran-6-one (1d).
2. Results and Discussion
2.1. Chemical Characterization
The structural elucidation of the flavanone 1 was reported by Ahluwalia et al. [13] and the
(2S) configuration structure by Narvaez et al. [14]. Flavanone 1 (Figure 1) was obtained (0.329 g) as
a yellow solid with a melting point of 200–202 ◦C. It showed a molecular ion of m/z 324 in the mass
spectrum, in addition to the peaks of typical fragmentations of previously described flavanones [15].
The molecular ion also confirmed the molecular formula C20H20O4. The infrared (IR) spectrum showed
bands for hydroxyl group in 3134 cm−1 and a band in 1634 cm−1 corresponding to a carbonyl group.
Characterization was also performed by spectroscopic techniques such as: 1H nuclear magnetic resonance
(NMR), 13C-NMR, correlated spectroscopy (COSY), distortion-less enhancement by polarization transfer
(DEPT), heteronuclear single quantum correlation spectroscopy (HSQC), (heteronuclear multiple bond
correlation) HMBC and nuclear overhauser enhancement spectroscopy (NOESY).
2.2. Pharmacomodulation
armacomodulation is a molecular design strategy in which an already established lead
compound is modified to improve its pharmacokinetic and/or pharmacodynamics parameters.
Flavanone 1 (as lead compound) was considered in the present work for the development of new
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active principles as new therapeutic agents with enhanced efficacy and bioavailability, and reduced
toxicity and undesired side effects [16].
2.2.1. Esterification
Esterification was one of the strategies to study the pharmacomodulation of the lead compound
flavanone 1. The ester derivative 1a allows one to increase the lipophilicity, which confers greater
capacity for the transport through cell membranes [16]. In many cases, the active substance needs to
reach the cytosol to exert its biological action. This could be an essential condition in the case of some
anticancer agents depending on their mechanisms of action. For this reason exogenous molecules
must first traverse the cell membrane. If the membrane transport is addressed by passive diffusion
the minimizing of the effective polarity of the desired compound maybe, improve its permeation
properties by esterification strategy shielding polar groups [17]. The esterification was performed with
acetic anhydride over pyridine to obtain the esterified derivate 1a (Scheme 1).
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The proposed reaction mechanism for this reactions is shown in Scheme 2, where acetic 
anhydride was used as the acylating agent, which is attacked by the pair of electrons of pyridine to 
give the intermediate switterion 1a.I, which by loss of an acetate ion leads to intermediate 1a.II, 
which in turn is attacked by the pair of electrons of the oxygen of the hydroxyl group from position 
6 of flavanone 1 to afford intermediate 1a.III, which by abstraction of the proton forms the 
intermediate 1a.IV plus a protonated pyridine, which is subsequently neutralized by the acetate 
anion regenerating the neutral pyridine and acetic acid to form the intermediate 1a.V, which 
corresponds to a mono-acetylated compound. The next stage of the reaction consists of the attack of 
the electron pair of intermediate 1a.V on the second molecule of intermediate 1a.II resulting the 
intermediate 1a.VI, in which by abstraction of the proton bounds to oxygen by a new molecule of 
pyridine leads to the formation of intermediate 1a.VII plus the protonated pyridine, which is 
subsequently neutralized with a second acetate anion to finalize the total reaction process of the 
product (1a). 
Flavanone 1a was obtained as a yellow solid substance with a melting point of 72–78 °C, which 
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mode and characteristic bands in the IR spectrum for ketone carbonyl to C-4, ester carbonyl at C-5 
and C-7, as well as double bond in prenyl moety and aromatic rings (rings B and C of flavanone). 
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and typical signals for an acetate group at 2.32 and 2.43 ppm. In the 13C-NMR spectrum the 
presence of two signals at 168.02 and 169.05 ppm belonging to the carbonyl of two ester groups 
were also observed. 
Scheme 1. Esterification reaction of (2S)-5,7-dihydroxy-6-(3-methyl-2-buten-1-yl)-2-phenyl-2,3-dihydro-4H-
1-Benzopyran-4-one (1) to obtain (2S)-5,7-bis(acetyloxy)-6-(3-methyl-2-buten-1-yl)-2-phenyl-2,3-dihydro-4H-
1-Benzopyran-4-one (1a).
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was use as the acyl ting agent, which is attacked by the pair of electrons of pyridine to give the
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Scheme 2. A plausible mechanism for the semi-synthesis of (2S)-5,7-bis(acetyloxy)-6-(3-methyl- 
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signals obtained from natural flavanone 1. Furthermore the 2D correlation spectrum 1H-13C, HSQC 
and NOESY confirmed the identity of the obtained modulated ester 1a. This compound is 
considered novel because was not reported previously in the literature. 
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confirmed by data reported by Filho et al. [21]. 
2.2.3. Cyclization 
Within the pharmacomodulation techniques, ring formation is an approach for the study of the 
active conformation in the starting molecule (lead compound). Since the product is a molecule with 
less conformational freedom, one of the most frequent drawbacks of this modification is that the 
introduction of structural elements might modify both the activity and the physicochemical 
properties of the natural flavanone 1. On the other hand, the formation of rings can lead to the 
Sche e 3. Methylation reaction of (2S)-5,7-dihydroxy-6-(3-methyl-2-buten-1-yl)-2-phenyl-2,3-dihydro-4H-1-
Benzopyran-4-o e (1) to produce (2S)-5-hydroxy-7-methoxy-6-(3-mehyl-2-buten-1-yl)-2-phenyl-2,3-dihydro-
4H-1-Benzopyran-4-one (1b).
Diazomentane (b) is prepared by hydrolysis of an ethereal solution of N-nitroso-N-methylurea (a)
with potassium hydroxide, obtaining methyl diazotate (c) as a subproduct as depicted in Scheme 4.
Once diazomethane (b) was prepared, it was reacted with flavanone 1 and diazomethane abstracted the
hydroxyl proton from the 7-position alcohol of flavanone 1 to form the alkoxide in intermediate 1b.I,
which subsequently abstracted the methyl from the methyl carbamate releasing molecular nitrogen
and resulting in the product 1b.
lec les , ,   f  
 
 
 . t l ti  ti  f ( )- , - i -( - t l - t - - l)- - l- , - i - 
- - - -  ( ) t   ( )- - - - t - -( - l- - t - - l)- - l- , - 
i - - - - -  ( ). 
i t   i    l i    t l l ti   it t l  
 it  t i  i , t i i  t l i t t     t  i t  i  
 .  i t    , it  t  it  l    i t  
t t  t  l t   t  iti  l l  l   t   t  l i  i  
i t i t  . , i  tl  t t  t  t l  t  t l t  l i  
l l  it   lti  i  t  t . 
 
 .  i  f  i- t i  f ( )- - - - t - -( - l- - t - 
- l)- - l- , - i - - - - -  ( ). 
 l l l t      ll  li , it  lti  i t     
l l  l  21 22 4.   t  i it  t  t i ti   i  t  
i ti  l , l t  l    ti  i .  1  
t     i il  t  t t   it  t  ti    i l t i l t .   
i  t  t  t l t ,  t i  t   iti   t i  t  t l t  
 i l t .   i  t  13  t . i i , t i   t   
t l  l ti   i  it  1 13  t ; t  t t l l i ti   
i   t  t   il  t l. . 
. . . li ti  
it i  t  l ti  t i , i  ti  i     t  t   t  
ti  ti  i  t  t ti  l l  l  . i  t  t i   l l  it  
l  ti l ,   t  t t   t i  i i ti  i  t t t  
i t ti   t t l l t  i t i  t  t  ti it   t  i i l 
ti   t  t l l  .  t  t  , t  ti   i   l  t  t  
Scheme 4. Proposed mechanism for semi-synthesis of (2S)-5-hydroxy-7-methoxy-6-(3-mehyl-2-buten-1-yl)-2-
phenyl-2,3-dihydro-4H-1-Benzopyran-4-one (1b).
e s f 9 ◦
f r 21 22 4. The IR s ectr i ite t t i ti
r hydroxyl groups, carbonyl keton double bond and aromatic rings. The 1H-NMR spectrum
of 1b was similar to that of 1 with the exception of a single signal t 3.83 ppm corresponding to
the methyl ether, now present in the C-7 po ition and matching the methyl ether carbon signal at
56.14 ppm i the 13C-NMR spectrum. Likewise, this was corroborated by heteronu lear c rrelation
obs rved in its 1H-13C-HSQC pectrum; the structural elucidation was confirmed by data reported by
Filho et al. [21].
. . .
ithin t e ar ac l ti t c i , ri f r ti i f r t t f t
ti i t t ti l l (l . l l it
l f , f t fi t t
Molecules 2017, 22, 1553 7 of 21
introduction of structural elements might modify both the activity and the physicochemical properties
of the natural flavanone 1. On the other hand, the formation of rings can lead to the creation of
new stereogenic centers, with all the repercussions that this entails in terms of racemic mixtures and
enantiomeric excesses among others. This cyclization strategy could have both structure—metabolism
and structure–toxicity relationship implications. It has been reported to improve the in vitro anticancer
activity against human cancer cell lines [22] of flavanones lead compounds.
The reaction conditions for obtaining modulated compound 1c (Scheme 5) were described by
Jain et al. [23], for carrying out the cyclization strategy between the hydroxyl group in position 7 and
prenyl group in position 6 at flavanone 1 to form a pyran 1c. This kind of synthesis strategy was also
described for other flavonoids [13].
Molecules 2017, 22, 1553 7 of 21 
 
creation of new stereogenic centers, with all the repercussions that this entails in terms of racemic 
mixtures and enantiomeric excesses among others. This cyclization strategy could have both 
structure—metabolism and structure–toxicity relationship implications. It has been reported to improve 
the in vitro anticancer activity against human cancer cell lines [22] of flavanones lead compounds. 
The reaction conditions for obtaining modulated compound 1c (Scheme 5) were described by 
Jain et al. [23], for carrying out the cyclization strategy between the hydroxyl group in position 7 
and prenyl group in position 6 at flavanone 1 to form a pyran 1c. This kind of synthesis strategy 
was also described for other flavonoids [13]. 
 
Scheme 5. Cyclization reaction of (2S)-5,7-dihydroxy-6-(3-methyl-2-buten-1-yl)-2-phenyl-2,3-dihydro- 
4H-1-Benzopyran-4-one (1) to form (8S)-5-hydroxy-2,2-dimethyl-8-prenyl-3,4,7,8-tetrahydro-2H,6H- 
Benzo[1,2-b:5,4-b′]dipyran-6-one (1c). 
As the plausible mechanism we propose that π electrons of the double bond of the prenyl 
group of flavanone 1 are excited by the effect of the temperature, reacting to abstract the proton of 
the formic acid leading to the formation of the tertiary carbocation of the intermediary 1c.I, that 
later is neutralized by the electrons of the oxygen of the hydroxyl group at the 7-position of the 
intermediate 1c.I to undergo an intramolecular cyclization producing to protonated intermediate 
1c.II, which when deprotonated by the anion-formate, leads to the preparation of compound 1c and 
formic acid was recovered, as illustrated in Scheme 6. 
The crude product was purified by preparative thin layer chromatography (TLC) to isolate 
derivate 1c and the melting point was determined in the range 128–130 °C. This compound 1c was a 
yellow solid. IR spectrum revealed the characteristic bands of lead flavanone 1 with the exception of 
the double bond carbon-carbon bands that appear in the natural flavanone 1 at 1642 cm−1, since the 
new compound 1c has methylenes. 
On the other hand, the 1H-NMR spectrum of compound 1c showed signals for the hydrogens 
on the C-3 and C-4 single bond. In the case of the hydrogens at C-1 of prenyl group of flavanone 1 
at 3.26 ppm they appear as a doublet, but in the case of the derivative 1c they are seen as a doublet 
of doublet of doublets at 2.62 ppm, relative to the neighboring hydrogens H-3α and H-3β and the 
hydrogen found in the same carbon atom 4. Furthermore, the signal at 5.24 ppm was observed as a 
triplet for the vinylogous hydrogen of the C-3 position in prenyl group at natural flavanone 1. 
However, in derivative 1c this signal changed in the 1H-NMR spectrum. A triple signal at 1.79 ppm 
was evidenced. In order to verify the cyclized nature of the derivative the signals of methylene 
carbons C-3 and C-4 were obtained, which were at 32.23 ppm and 16.13 ppm in the 13C-NMR 
spectrum, respectively. These same signals could be observed in DEPT experiment as methylene 
carbons. The signal of C-2 was observed at 76.67 ppm, corresponding to the carbon that supports 
the methyl groups, which were observed at 27.05 ppm and 27.23 ppm, respectively, and correlated 
with the methyl groups characteristic of the prenyl moiety at natural flavanone 1. 
Sche e 5. Cyclization reaction of (2S)-5,7-dihydroxy-6-(3- ethyl-2-buten-1-yl)-2-phenyl-2,3-dihydro-
4 -1-Benzopyran-4-one (1) to for (8S)-5-hydroxy-2,2-di ethyl-8-prenyl-3,4,7,8-tetrahydro-2 ,6 -
Benzo[1,2-b:5,4-b′]dipyran-6-one (1c).
s the plausible mechanism we prop se that pi electrons f the double bond of the prenyl group
of flavanone 1 are excit d by the effect of the temperature, reacting to abstr ct the proton of the
formic acid leading to the formation of the tertiary carbocation of the intermediary 1c.I, that later is
neutralized by the electrons of the oxygen of the hydroxyl group at the 7-position of the intermediate
1c.I to undergo an intramolecular cyclization producing to protonated intermediate 1c.II, which when
deprotonated by the anion-formate, leads to the preparation of compound 1c and formic acid was
recovered, as illustrated in Scheme 6.
e cr e r ct s rifie re r ti e t i l er c r t r ( ) t is l te
eri ate 1c a t e elti i t as deter ined in the range 128–130 ◦C. This compound 1c was
a yellow solid. IR spectrum revealed the characteristic bands of lead fla a o e 1 it t e exce tio of
t e le car -car a s t at a ear in the natural flavanone 1 at 1642 cm− , si ce t e
e co o 1c as et le es.
t e t er a , t e 1 - s ectr f c 1c s e si als f r t e r e s
t e -3 a -4 si le . I t e case f t e r e s at -1 f re l r f fla a e 1
at 3.26 t e a ear as a o let, t i t e case of t e eri ati e 1c t e are see as a o let
of o let of o lets at 2.62 , relati e to t e ei ori ro e s -3 a -3 a t e
ro e fo i the same carbon atom 4. Furthermore, the signal at 5.24 ppm was observed
as a triplet for the vinylogous hydrogen of the C-3 position in prenyl group at natural flavanone 1.
o ever, in derivative 1c this signal changed in the 1H-NMR spectrum. A triple signal at 1.79 ppm was
evidenced. In order to verify the cyclized nature of the derivative the signals of methylene carbons C-3
and C-4 were obtained, hich were at 32.23 ppm and 16.13 ppm in the 13C-NMR s ectrum, respectively.
These same signals could be observed in DEPT experiment as methylene carbons. The signal of C-2
was observed at 76.67 ppm, corresponding to the carbon that supports the methyl groups, which
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The intramolecular cyclization of flavanone 1 to form compound 1d by the use of 2,3-dichloro-
5,6-dicyanobenzoquinone (DDQ) under anhydrous conditions is schematized in the Scheme 8. As a first
step in the reaction the DDQ was protonated by abstracting the proton from the alcohol of position 7
of flavanone 1, to produce intermediate 1d.I and DDQH⊕, which aromatizes by abstraction of hydride
and forms DDQH2 with intermediate 1d.II. Once the intermediate 1d.II is formed and a cationic
transposition occurs generating the resonant form to obtain the more stable tertiary carbocation
corresponding to intermediate 1d.III, then the alkoxy anion carries out intramolecular cyclization by
compensating the carbocation charge deficiency and thereby giving compound 1d.
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2H,6H-Benzo[1,2-b:5,4-b′]dipyran-6-one (1d).
The IR spectrum of the vinylogous cyclization product 1d showed characteristic bands of hydroxyl,
keton carbonyl groups and carbon-carbon bond of ar matic ring. The 1H-NMR spectrum exhibited
doublet signals at 5.51 ppm and 6.62 ppm, corresponding to the vinylogous hydrogens in positions H-3
and H-4, respectively. These were different from derivative 1c. The C=C double bond was confirmed
by 13C-NMR signals at 126.38 ppm and 115.50 ppm for the C-3 and C-4 position carbons, respectively.
The rest of the observed signals of the 1H-NMR and 13C-NMR spectra of derivatives 1c and 1d revealed
significant changes [25]. Derivative 1d was previously reported by Manchanda et al. in 1976 [26].
2.3. Cytotoxic Assay of Free Compounds
2.3.1. Brine Shrimp (Artemia salina)
The results in Table 1 show the percentage mortality values of natural flavanone 1 and its
derivatives 1a, 1b, 1c and 1d against Artemia salina; these values with 95% confidence intervals values
were calculated by the probit analysis method [27]. It could be observed that natural flavanone 1
did not show important percentage of m rtali y, si ce a 100 ppm c ncentrati n only 11.5% nauplii
mortality was detected. At the lowest concentration no toxicity was observed. However, the results
allowed ascertaining changes in the biological activity due to the structural modifications applied.
Derivatives 1a and 1c showed higher mortality rates of 36.7% and 50%, respectively, at the lowest
concentration (10 ppm).
It was possible to see that the mortality rate results for 1a and 1c indicate the threshold of
effectiveness as the effect was not modified even at increasing concentrations. Regarding derivatives
1b and 1d, it was possible to conclude that the structural changes resulted in a reduction of the effect
of flavanone 1, which c rroborated that the cytotoxicity activity observed in flava one 1 is related to
the presen e of the hydroxyl group in po ition 7, as well as the free disp sition of the prenyl group in
position 6. The implication of double bond of both the prenyl group and pi-electrons of derivative 1d
was also recognized. They had not correlation since the final cytotoxicity results were different.
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Table 1. Percentage mortality values of natural flavanone 1 and derivatives 1a, 1b, 1c and 1d against
Artemia salina.
Compounds Concentration (ppm/µM) Percentage Mortality Values (%)
1
0/0 0.0
10/0.03083 0.0
100/0.3083 11.5
1000/3.0828 43.2
1a
0/0 0.0
10/0.0245 36.7
100/0.245 40.0
1000/2.45 30.0
1b
0/0 0.0
10/0.02955 10.0
100/0.29551 0.0
1000/2.9551 0.0
1c
0/0 0.0
10/0.03083 50.0
100/0.3083 45.0
1000/3.0828 40.0
1d
0/0 0.0
10/0.03102 13.3
100/0.3102 0.0
1000/3.102 0.0
Therefore, as already mentioned, the change from 1 to 1b led to the loss of pharmacological
activity at least in this biological assay. In the case of 1d, the activity may be unpredictable and
the conjugated double bond may result in the generation of cytotoxic metabolites. Additionally, an
antimicrobial activity has been reported for these kinds of prenylated flavonoids due to the existence
of pi-electrons. These compounds are more hydrophobic than the conventional flavonoids, and thus
they may penetrate easily through the cell membrane [28]. Results show that all compounds have a
LC50 > 1000 ppm (3.0820 µM).
2.3.2. Cell Viability MiaPaCa-2 Cells
The MiaPaCa-2 cell line (pancreatic cancer cells) is used as an in vitro model to study pancreatic
ductal adenocarcinoma carcinogenesis [29]. The results showed that derivatives 1b and 1d decreased
cell viability in the concentration range 10–50 µM and 25–50 µM, respectively. Cell viability in these
ranges of concentration was lower than that observed in flavanone 1 (Table 2). It can be hypostatized
that the observed cytotoxic activity of derivatives 1b and 1d may be due to existence of the methyl
ether group at position 7 in 1b, and the formation of 3,4-dehydropyran ring in 1d. Other prenylated
flavanones with similar structures, such as those derived from naringenin, aromadendrin, tangeretin,
among others, have been considered as potential cancer chemopreventive agents for their similar
activities on cell viability at low concentrations [30,31].
Table 2. Percentage cell viability (%) of MiaPaCa-2 of natural flavanone 1 and derivatives 1a, 1b, 1c
and 1d. Concentration values are in µM, and cell viability are expressed as mean ± SD. All data were
obtained from three replicates.
Concentration
Percentage Cell Viability (%) of MiaPaCa-2
1 1a 1b 1c 1d
DMSO and
Control 91.35 ± 4.18 100.28 ± 9.39 94.27 ± 10.30 95.99 ± 1.14 97.47 ± 2.22
5 µM 88.08 ± 1.99 110.67 ± 2.03 91.65 ± 2.04 102.18 ± 1.05 97.24 ± 1.20
10 µM 59.63 ± 3.54 96.19 ± 1.40 58.94 ± 4.58 101.23 ± 1.45 98.81 ± 1.70
25 µM 49.80 ± 1.19 79.22 ± 1.16 22.56 ± 1.69 54.82 ± 2.84 35.35 ± 2.50
50 µM 38.48 ± 1.52 36.54 ± 9.34 28.74 ± 2.53 65.85 ± 7.46 27.86 ± 1.25
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A structural analysis could be performed, as well as a mechanism of action elucidation based on
the bioisomeric criteria in drug design [32]. Equally, as a result of this analysis regarding different
antineoplastic agents used in pancreatic cancer treatment, which have been recommended by the
American Cancer Society, such as 5-fluorouracil, paclitaxel, irinotecan, cis-platinum and gemcitabine,
a similarity in functional groups such as the aromatic hydrocarbons and amine can be observed. In the
course of the analysis with derivatives providing the lowest cell viability (compounds 1b and 1d), these
compounds possess ether groups and double bonds, as well as aromatic hydrocarbons. The first two
types of groups are classical isosteres of the amino group [31], which is responsible of the decrease
in cell viability against MiaPaCa-2 cells. On the other hand, in an attempt to determine the possible
mechanism of action, apoptosis by similarity with anti-neoplastic drugs it could be proposed [33]
as it has been demonstrated that flavonoids are potential agents in the preventive treatment of
pancreatic cancer [34].
2.4. PLGA NPs
The use of polymeric drug delivery systems for effective encapsulation and targeting
involves the right choice of polymer composition, stabilizer, solvent and elaboration technique [8].
The encapsulation of cytotoxic drugs (natural and derivatives) in particulate delivery systems
represents an innovative alternative to minimize side effects, while preserving the cytotoxic activity.
Among these polymers, PLGA, which was approved by the U.S. Food and Drug Administration
(FDA), has been extensively used for controlled drug delivery systems because of its biocompatibility
and biodegradability [35]. Poloxamer 188 (P188) was chosen as surfactant to stabilize this particulate
system in aqueous suspension due to its non-ionic properties. It is also accepted by the regulatory
authorities for human administration [36]. Additionally, it contributes to the stabilization of the
colloidal system [37]. Based on these considerations, PLGA unloaded NPs (blank NPs), as well as
flavanone (natural and derivatives)-loaded NPs were developed at a concentration of 1.5 mg/mL.
The concentrations of each natural flavanone 1 and derivatives 1a, 1b, 1c and 1d loaded PLGA NPs
and entrapment efficiency are expressed in Table 3.
Table 3. Compound concentrations (mM) loaded in PLGA NPs and entrapment efficiency (EE %).
PLGA Nanoparticles Concentration (mM) Entrapment Efficiency (EE %)
NPs1 4.62 80.00 ± 4.75
NPs1a 3.67 88.47 ± 4.18
NPs1b 4.43 85.00 ± 5.80
NPs1c 4.62 78.28 ± 5.85
NPs1d 4.65 78.75 ± 4.34
These results show that all NPs entrapped between 78.28 and 88.47% of the compounds. The EE
was high enough and ranged from 88.47% for NPs1a to 85.00% for NPs1b, these values of PLGA NPs
were in agreement or even higher than other authors [38] and could be explained by the hydrophobic
nature of compounds. Table 4 summarizes the obtained NPs characterization results. Characterization
techniques revealed spherical shaped NPs with an overall average size (Z-average) ranging from
141.633 ± 0.773 to 205.200 ± 0.265 nm. The width of the size distribution expressed as polydispersity
index (PDI) ranged between 0.058 ± 0.053 and 0.101 ± 0.031. The surface charge of NPs was obtained
in terms of ZP values, which ranged from −10.633 ± 0.231 to −4.237 ± 0.242 mV.
As can be observed from Table 4, the particle size distribution was very narrow for NPs1a,
NPs1c and NPs1d, being the highest PDI value 0.101 for NPs1c, which denoted the existence of
a monodisperse systems. Additionally, the highest Z-average value was observed in NPs1. Value of
ZP in PLGA NPs depends on several factors: type of PLGA, type of drug encapsulated and type of
stabilizing agent used during preparation. All NPs showed negative charges ranging from −4.24
to −10.6 mV, probably due to the free carboxylic end-groups of the polymer chains in presence of
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water [39]. The intermolecular bonds between carbonyl group of PLGA and -OCH3 and -OH groups
of derivative 1b in NPs1b could explain its lowest Z-average and ZP values value.
Table 4. Z-Average (nm), polydispersity index and zeta potential (mV) of developed NPs. All data
were obtained from three replicates and values are expressed as the mean ± SD.
Nanoparticles Z-Average (nm) Polydispersity Index Zeta Potential (mV)
Blank 195.667 ± 1.069 0.054 ± 0.016 −4.237 ± 0.242
NPs1 205.200 ± 0.265 0.058 ± 0.053 −8.250 ± 0.346
NPs1a 178.033 ± 1.332 0.080 ± 0.004 −9.053 ± 0.323
NPs1b 141.633 ± 0.777 0.086 ± 0.017 −10.633 ± 0.231
NPs1c 175.167 ± 0.603 0.101 ± 0.031 −6.480 ± 0.377
NPs1d 173.400 ± 1.587 0.064 ± 0.007 −6.647 ± 0.405
Figure 3 shows the transmission electron microscopy (TEM) images of the NPs. The morphology
of NPs where most of particles had round, uniform shapes can be observed. Particle size measured by
TEM was generally well correlated with that found using photon correlation spectroscopy (PCS).
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Figure 3. Transmission electron microscopy (TEM) images of blank NPs (A); and drug loaded NPs:
NPs1 (B); NPs1a (C); NPs1b (D); NPs1c (E) NPs1d (F). Bar lengths: 500 nm (A), 200 nm (B–F).
Table 5 shows average NPs diameters obtained from TEM. These results were smaller than those
obtained by Dynamic Light Scattering (Table 3). However, the NPs size behavior is similar, since the
formulation NPs1b in both cases shows the smaller average NPs size, and those with larger size are
blank NPs, and NPs loaded with natural flav one (NPs1).
Table 5. Average diameter of NPs (nm) obtained by image analysis software (ImageJ 6.0) from TEM.
All data were obtained from 100 particles d values are expressed as mean ± SD.
Nanoparticles Z-Average (nm)
Blank 157.295 ± 10.405
NPs1 112.779 ± 19.232
NPs1a 76.430 ± 7.197
NPs1b 54.351 ± 7.156
NPs1c 102.228 ± 11.656
NPs1d 81.933 ± 8.500
Molecules 2017, 22, 1553 13 of 21
2.5. Cytotoxic Activity of NPs
The results of cytotoxic activity of NPs against MiaPaCa-2 cell line are listed in Table 6. Blank NPs
exhibited no cytotoxicity against MiaPaCa-2 cells, and thus did not affect the results of the active
substances loaded in NPs. NPs1a and NPs1b were the formulations which exhibited the lowest cell
viability percentages. Therefore and taking into account the previous results of cytotoxicity of free
flavanone 1a (Table 2) it could be concluded that the encapsulation of this derivative in the NPs
led to an improvement of the cytotoxic efficacy. At 50 µM concentration free flavanone 1a reached
36.54% of cell viability whereas NPs1a reached 11.22%. On the other hand, NPs1b showed similar
values of cell viability compared with free derivative 1b at 50 µM, 31.88 ± 2.43% and 28.74 ± 2.53%.
In this case, additional advantages provided by the vehicle might be expected. Finally, at 100 µM
concentration values optimal values of cell viability were obtained 1.76% and 8.47% for NPs1a and
NPs1b, respectively.
Table 6. Percentage cell viability (%) of MiaPaCa-2 against developed NPs. Concentration values
are in µM for NPs, and cell viability is expressed as mean ± SD. All values were obtained from
three replicates.
Concentration
Percentage Cell Viability (%) of MiaPaCa-2 against Developed NPs
Blank NPs NPs1 NPs1a NPs1b NPs1c NPs1d
0 µM 100 ± 0.00 100 ± 0.00 100 ± 0.00 100 ± 0.00 100 ± 0.00 100 ± 0.00
10 µM 111.24 ± 6.44 107.75 ± 8.18 69.62 ± 2.26 97.12 ± 25.64 89.44 ± 11.74 83.51 ± 16.33
50 µM 111.24 ± 6.44 102.68 ± 1.64 11.22 ± 2.36 31.88 ± 2.43 84.66 ± 5.60 43.59 ± 9.60
75 µM 113.40 ± 15.50 100.75 ± 4.00 3.20 ± 1.88 15.88 ± 2.40 80.68 ± 9.03 37.30 ± 4.33
100 µM 113.40 ± 15.50 83.24 ± 13.81 1.76 ± 1.01 8.47 ± 1.05 85.69 ± 2.41 32.85 ± 2.01
This improvement provided by the vehicle could be due to the different interaction mechanism
between free compound and the NPs vehicle in the cellular uptake. The free compound uptake may
be due to a diffusion mechanism, so after attaining saturation inside the cytoplasm further entry will
be restricted and the internalized fraction inside the cell exerts the cytotoxic activity [40]. On the
other hand, as is known this kind of NPs are an ideal for formulation due to its wide medical use,
biocompatibility, and safety. 6-Coumarin loaded in PLGA NPs was reported in the literature and
they had been shown that have multiple endocytosis internalization mechanism and to know how
the mechanism action. We consider could be to realize a study the internalization of nanoparticles in
cell surface [41]. Once in the cytoplasm the drug encapsulated is released from NPs as the vehicle
degrades providing a sustained release exerting its cytotoxic effect [42].
All the studied compounds and loaded NPs exhibited a typical dose dependent cytotoxic effect
represented in Figure 4. Finally, NPs1a was the formulation that showed the best results of cytotoxicity.
These results suggest that the compound 1b might be a possible candidate for future investigations
about cancer chemotherapy studies. The flavanone 1 and its derivatives with specified cytotoxic activity
could be tested against different types of tumor cell lines. Besides, new nanostructured formulations
will also be developed in the search of new therapeutics targets such as inflammation. Consequently,
further studies will be conducted to investigate their possible mechanism of action.
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3. t ri l t s
3.1. Plant aterial
Leaves of E. platycarpa Pennell & Safford (Fabaceae) were collected from the municipality of
Tetipac, Guerrero State (Mexico). Voucher specimens were authenticated by Prof. Ramiro Cruz Durán
(voucher specimen 1325) and were stored at the Sciences Faculty Herbarium facilities (Universidad
Nacional Autónoma de éxico, exico City, Mexico).
3.2. Materials and Instrumentation
Solvents, deuterated solvents and reagents were all purchased from Sigma-Aldrich (Toluca de
Lerdo, Mexico). Fourier transform infrared absorption spectroscopy (FTIR) measurements were
performed by using a Nicolet 6700 FTIR spectrometer (Thermo Electron Scientific; Madison, WI, USA)
in the range of 525–4000 cm−1 equipped with a KBr beam splitter, a deuterated triglycine sulfate
(DTGS) detector and OMNIC® software (Thermo Electron). 1H- and 13C-NMR spectra were recorded
in a Unity NMR spectrometer (Varian Inova, Palo Alto, CA, USA) operating at 400 MHz for 1H and
200 MHz for 13C nuclei. Fifteen mg of each compound were prepared in deuterated chloroform
(CDCl3) and tetramethylsilane (TMS) was used as internal standard. The molecular formulae of
compounds 1a, 1b, 1c and 1d was confirmed by FABSMS analysis performed on a JMX-AX 505 HA
mass spectrophotometer (JEOL Ltd., Tokyo, Japan).
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3.3. Preparation of Methanolic Extract
The methanolic extract of E. platycarpa leaves was obtained by maceration method. Leaves were
dried at room temperature in the shade. Once the leaves were dried they were pulverized and extracted
with methanol by maceration at room temperature three times (100 g of dried vegetable material per
1000 mL of methanol). Then, the extractions were performed and the solvent was removed under
reduced pressure to obtain the corresponding residues [14].
3.4. Isolation of Compound (2S)-5,7-Dihydroxy-6-(3-methyl-2-buten-1-yl)-2-phenyl-2,3-dihydro-4H-1-
benzopyran-4-one (1)
From the methanolic extract of E. platycarpa leaves the prenylated flavanone compound 1 (329 mg),
was isolated as yellow solid by column chromatography at reduced pressure using silica gel HF 254.
Then the flavanone was purified and characterized by direct TLC comparison with an original sample
available at the laboratory. It was also analyzed by 1H-NMR (400 MHz) and 13C-NMR, as well as mass
spectrometry checking their identities by comparison with the previously published spectroscopic data [14].
Compound 1 can also be found (CAS No.: 55051-77-9).
3.5. Preparation of Derivatives
(2S)-5,7-Bis(acetyloxy)-6-(3-methyl-2-buten-1-yl)-2-phenyl-2,3-dihydro-4H-1-Benzopyran-4-one (1a).
Compound 1 (50.00 mg 0.1541 mmol) in acetone (2 mL) was treated with a (2:1) mixture of Ac2O:Py
(4 mL) and room temperature for 24 h. After usual work-up 39.8 mg of a residue was obtained, which
was purified by TLC (eluting with 9:1 n-hexane:EtOAc) to give compound 1a, as a yellow solid in
79.6% yield. Melting point 72–78 ◦C. 1H-NMR (400 MHz, chloroform-d, δ; ppm) 7.43 (m, 5H, 2-C6H5),
6.78 (s, 1H, 8-H), 5.46 (dd, J = 12.8, 3.2 Hz, 1H, 2-H), 5.00 (tc, J = 6.8, 1.2 Hz, 1H, 2-H, prenyl moety),
3.18 (sa, 1H, 1-H, prenyl moety), 3.06 (dd, J = 17.2, 12.8 Hz, 1H, 3-H), 2.79 (dd, J = 17.2, 3.2 Hz, 1H,
3-H), 2.43 (s, 3H, 5-OCOCH3), 2.32 (s, 3H, 7-OCOCH3), 1.75 (s, 3H, 3-CH3, prenyl moety), 1.70 (s, 3H,
4-H, prenyl moety); 13C-NMR (200 MHz, Chloroform-d, δ; ppm) 18.26 (q, 3-CH3, prenyl moety); 21.32
(q, 7-OCOCH3); 21.44 (q, 5-OCOCH3).; 23.35 (t, 1-C, prenyl moety); 25.97 (q, 4-C, prenyl moety); 45.67
(t, 3-C); 79.63 (d, 2-C); 110.13 (d, 8-C); 111.97 (s, 4a-C); 120.99 (d, 2-C, prenyl moety); 120.99 (s, 6-C);
126.16 (d, 2′-C/6′-C); 128.83 (d, 3′-C/5′-C); 128.86 (d, 4′-C); 132.36 (s, 3-C, prenyl moety); 138.18 (s, 1′-C);
149.11 (s, 5-C); 154.66 (s, 7-C); 160.79 (s, 8a-C); 168.02 (s, 5-OCOCH3); 169.05 (s, 7-OCOCH3); 189.20 (s,
4-C). IR; 2921.8 cm−1, 2371.9 cm−1, 1770.6 cm−1, 1688.7 cm−1, 1608.0 cm−1, 1451.5 cm−1, 1370.5 cm−1,
1283.0 cm−1, 1193.5 cm−1, 1155.3 cm−1, 1107.0 cm−1, 1005.9 cm−1, 895.9 cm−1, 764.6 cm−1, 699.3 cm−1,
577.8 cm−1. HR-MS (ESI), calcd. for C24H24O6: [M + H]+ 409.1573, found: 409.1853 ([M + H]+).
(2S)-5-Hydroxy-7-methoxy-6-(3-mehyl-2-buten-1-yl)-2-phenyl-2,3-dihydro-4H-1-Benzopyran-4-one (1b).
A solution of flavanone 1 (50.00 mg; 0.1541 mmol) in a mixture of absolute ethanol and ethyl ether (1:1) was
treated with an ethereal solution of diazomethane prepared from nitromethyl urea (2.8 g). The methylation
agent was added in small lots and cooled in ice for 10 min. The color of the reaction changed to pale
yellow and the reaction mixture was then kept in an ice-chest for 5 h. The container was closed with a cork
with a thin tube to enable any gases released to escape. The solvents were completely distilled off and the
residue taken up in a vial. After the solution was concentrated and cooled in ice-water for a few hours the
methyl ether crystallized. It was purified by recrystallization to give a yellow solid in 58% yield (29.0 mg).
Melting point 95–96 ◦C. 1H-NMR (400 MHz, chloroform-d, δ; ppm) 12.05 (s, 1H, 5-OH); 7.43 (m, 2-C6H5);
6.09 (s, 1H, 8-H); 5.40 (dd, J = 13.2, 3.2 Hz, 1H, 2-H); 5.18 (t, J = 7 Hz, 1H, 2-H, prenyl moety); 3.83
(s, 3H, 7-OCH3); 3.26 (d, J = 7 Hz, 1H, 1-H, prenyl moety); 3.08 (dd, J = 17.2, 13.2 Hz, 1H, 3a-H); 2.79
(dd, J = 17.2, 3.2 Hz, 1H, 3b-H); 1.77 (s, 3H, 3-CH3, prenyl moety); 1.67 (s, 3H, 4-H, prenyl moety).
13C-NMR (200 MHz, Chloroform-d, δ; ppm) 18.08 (q, 3-CH3, prenyl moety); 21.37 (t, 1-C, prenyl moety);
26.15 (q, 4-C, prenyl moety); 43.79 (t, 3-C); 56.14 (q, 7-OCH3); 79.62 (d, 2-C); 91.24 (s, 8-C); 103.16 (s,
4a-C); 110.29 (d, 6-C); 122.46 (d, 2-C, prenyl moety); 126.35 (d, 4′-C); 126.35 (d, 2′-C/6′-C); 129.082
(d, 3′-C/5′-C); 131.91 (s, 3-C, prenyl moety); 138.68 (s, 1′-C); 160.42 (s, 5-C); 161.51 (s, 8a-C); 165.66 (s,
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7-C); 195.92 (s, 4-C). IR; 3449 cm−1, 2918.9 cm−1, 1717.6 cm−1, 1647.5 cm−1, 1612.2 cm−1, 1485.3 cm−1,
1445.6 cm−1, 1358.3 cm−1, 1294.7 cm−1, 1204.9 cm−1, 1157.1 cm−1, 1099.3 cm−1, 995.5 cm−1, 901.6 cm−1,
810.8 cm−1, 742.5 cm−1, 696.2 cm−1, 632.4 cm−1, 554.7 cm−1, 445.7 cm−1. HR-MS (ESI), calcd. for
C21H22O4: [M + H]+ 339.1518, found: 339.1604 ([M + H]+). It was also compared with data available
in literature [21]. Compound 1b can also be found (CAS No.: 55051-79-1).
(8S)-5-Hydroxy-2,2-dimethyl-8-prenyl-3,4,7,8-tetrahydro-2H,6H-Benzo[1,2-b:5,4-b′]dipyran-6-one (1c).
A formic acid solution (20 mL) containing 1 (50.00 mg, 0.1541 mmol) was heated under reflux up to
60 ◦C for 1.5 h, and then it was left to cool for 6 h at room temperature. The crude of the reaction
product was extracted by ethyl acetate (EtOAc). Later, it was washed 3 times with water and the
dampness was eliminated with anhydrous Na2SO4. The compound 1c was obtained as a yellow
solid in 87.2% yield (43.6 mg), after removal of the solvent. Melting point 128–130 ◦C [43]. 1H-NMR
(400 MHz, chloroform-d, δ; ppm) 12.39 (s, 1H, 5-OH); 7.44 (m, 5H, 8-C6H5); 5.95 (s, 1H, 10-H); 5.38 (dd,
J = 12.8, 3.2 Hz, 1H, 8-H); 3.06 (dd, J = 17.2, 12.8 Hz, 1H, 7-Hα); 2.80 (dd, J = 17.2, 3.2 Hz, 1H, 7-Hβ);
2.62 (ddd, J = 6.8, 2 Hz, 2H, 4-H); 1.79 (t, J = 6.8 Hz, 2H, 3-H); 1.34 (s, 6H, 2-CH3). 13C-NMR (200 MHz,
chloroform-d, δ; ppm) 16.13 (t, 4-C); 27.05 (q, 2-CH3); 27.23 (q, 2-CH3); 32.23 (t, 3-C); 43.86 (t, 7-C); 76.67
(s, 2-C); 79.12 (d, 8-C); 96.43 (d, 10-C); 102.30 (s, 4a-C); 102.42 (s, 5a-C); 126.16 (d, 2′-C/6′-C); 128.72 (d,
4′-C); 128.82 (d, 3′-C/5′-C); 138.73 (s, 1′-C); 160.21 (s, 5-C); 161.28 (s, 10a-C); 162.82 (s, 9a-C); 195.50 (s,
6-C). IR; 3753 cm−1, 3448 cm−1, 2921 cm−1, 2371 cm−1, 1637 cm−1, 1447 cm−1, 1376 cm−1, 1305 cm−1,
1168 cm−1, 1119 cm−1, 899 cm−1, 805 cm−1, 758 cm−1, 694 cm−1, 607 cm−1, 479 cm−1. HR-MS (ESI),
calcd. for C20H20O4: [M + H]+ 325.1362, found: 325.1403 ([M + H]+).
(8S)-5-Hydroxy-2,2-dimethyl-8-phenyl-7,8-dihydro-2H,6H-Benzo[1,2-b:5,4-b′]dipyran-6-one (1d).
Flavanone 1 (50.00 mg, 0.1541 mmol) was treated with 2,3-dichloro-5,6-dicyanobenzoguinone (DDQ,
40.00 mg) in equimolar proportions (1:4) under reflux up to 78 ◦C in sodium-dried benzene (10 mL) for
5 h . The crude reaction product (40 mg) was submitted to TLC eluted with a 3:7 hexanes-CH2Cl2
mixture to obtain the compound 1d [25] in 52% yield (26 mg). 1H-NMR (400 MHz, chloroform-d, δ;
ppm) 12.30 (s, 5-OH); 7.45 (m, 5H, 8-C6H5); 6.62 (d, J = 10 Hz, 1H, H-4); 5.97 (s, 1H, H-10); 5.51 (d, J =
10 Hz, 1H, H-3); 5.40 (dd, J = 13.2, 3.2 Hz, 1H, H-8); 3.10 (dd, J = 17.2, 13.2 Hz, 1H, H-7α); 2.81 (dd, J =
17.2, 3.2 Hz, 1H, H-7β); 1.44 (s, 3H, 2-CH3); 1.43 (s, 3H, 2-CH3). 13C-NMR (200 MHz, chloroform-d,
δ; ppm) 28.56 (q, 2-CH3); 28.64 (q, 2-CH3).43.59 (t, 7-C); 78.52 (s, 2-C); 79.31 (d, 8-C); 96.50 (d, 10-C);
103.07 (s, 5a-C); 103.30 (s, 4a-C); 115.50 (d, 4-C); 126.38 (d, 3-C); 126.50 (d, 2′-C/6′-C); 128.39 (d, 4′-C);
129.054 (d, 3′-C/5′-C); 138.648 (s, 1′-C); 158.66 (s, 5-C); 162.53 (s, 10a-C); 162.37 (s, 9a-C); 195.97 (s,
6-C); IR; 3433 cm−1, 2927 cm−1, 2871 cm−1, 2366 cm−1, 1735 cm−1, 1637 cm−1, 1458 cm−1, 1372 cm−1,
1292 cm−1, 1166 cm−1, 1124 cm−1, 981 cm−1, 901 cm−1, 762 cm−1, 695 cm−1, 480 cm−1. HR-MS (ESI),
calcd. for C20H18O4: [M + H]+ 323.1267, found: 323.1267 ([M + H]+). Compound 1d can also be found
(CAS No.: 882846-01-7).
3.6. Preparations PLGA NPs
NPs loaded with natural flavanone 1 and derivatives 1a, 1b, 1c and 1d were prepared by the
solvent displacement technique reported by Fessi et al. [44]. Briefly, a 50:50 organic solution of PLGA
(90 mg) in acetone (25 mL) containing the drug (1.0 mg/mL) was poured under moderate stirring
into P188 aqueous solution (10 mL, 10 mg/mL, pH = 3.5). The acetone was then evaporated and
the volume of NP dispersion was concentrated under reduced pressure on a B-480 rotary evaporator
(Büchi, Labortechnik AG, Flawil, Switzerland) [8]. Once the organic solvent was removed the obtained
NPs were cleaned using repeated cycles of centrifugation and resuspension in double distilled water.
3.6.1. Particle Size Analysis
The size of NPs was determined by PCS by using a Zetasizer Nano ZS (Malvern Instruments,
Malvern, UK), a non-invasive, well established technique for measuring the size of particles in the
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submicron region, providing in parallel the PDI. Samples were directly placed into the module and the
data were collected at room temperature.
3.6.2. Zeta Potential Measurements
The ZP of NPs was measured using a Zetasizer Nano ZS (Malvern Instruments, Malvern, UK).
This instrument also allows determining the electrophoretic mobility to assess the surface electrical
charge of particles. Samples were diluted in purified water adjusting conductivity (50 µS/cm) with
sodium chloride solution (0.9% w/v) in order to avoid fluctuations of the ZP caused by differences in
the conductivity of distilled water [45]. The ZP was calculated from the electrophoretic mobility using
the Helmholtz—Smoluchowski equation [46].
3.6.3. Morphological Studies
Morphological examination of polymeric NPs was performed by TEM with a JEM-1010
microscope (JEOL Ltd., Tokyo, Japan). Briefly, one drop of each sample was deposited on copper grids
covered with a layer of Formvar® standing for 4 min. The grids were then stained with one drop
of 2% uranyl acetate solution and allowed to dry for 5 min before examination. Image analysis was
performed using the ImageJ 1.46r analysis software (Wayne Rasband, National Institutes of Health
(NIH), Rockville, MD, USA) [47]. For this task 100 images of each NPs type were analyzed.
3.6.4. Entrapment Efficiency (EE %)
The entrapment efficiency (EE) of each compound 1, 1a, 1b, 1c and 1d loaded polymeric
NPs was determined by measuring the concentration of free drug in the dispersion medium.
The non-entrapped compound 1, 1a, 1b, 1c and 1d was separated by filtration/centrifugation technique
using Amicon centrifugal filter devices equipped with 100 KDa Ultracel membrane (Millipore
Corporation, Billerica, MA, USA) at 3000 rpm for 12 min on a Sigma 301K centrifuge (Sigma, Barcelona,
Spain). Prior to filtration/centrifugation each sample was diluted (1:20) with ethanol/water (70:30)
solution to avoid deposition of free compounds (possibly crystallized in the aqueous phase) onto NP
surface avoiding erroneous overestimation of the EE. NPs were then retained on the membrane filter
while the hydro-ethanolic solution containing the free compound crossed the membrane. The amount of
compound in this solution was established using HPLC analysis. The natural flavanone 1 and derivatives
1a, 1b, 1c and 1d entrapment efficiency (EE %) was calculated as indicated in the formula below:
EE % =
Total amount of compound − Free amount of compound
Total amount of compound
× 100 (1)
3.7. Cytotoxic Assays
3.7.1. Brine Shrimp, Artemia salina Assay
The shrimp lethality assay was performed as previously reported by Mayer et al. [48]. It is based
on the ability to kill laboratory cultured Artemia salina brine shrimp nauplii. The assay is considered
a useful tool for preliminary assessment of toxicity. It has also been used for the detection of fungal
toxins, plant extract toxicity, heavy metals, cyanobacteria toxins, pesticides, and cytotoxicity testing of
dental materials.
Dried cysts were incubated (1 g/L) in seawater at 28–30 ◦C with strong aeration, under a
continuous light regime. Approximately 12 h after hatching, the phototropic nauplii were collected
with a pipette and concentrated in a small vial. Ten brine shrimp were transferred to each well using
adequate pipette. Toxicity was determined after 24 h of exposure. The numbers of survivors were
counted and the percentages of dead ones were calculated. Larvae were considered dead if they did not
exhibit any internal or external movement during several seconds of observation. Percentage mortality
values with 95% confidence intervals values were calculated by the probit analysis method [27,49].
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Natural flavanone 1 and derivatives 1, 1b, 1c and 1d were tested at concentration level of 1000, 100
and 10 ppm. All sample stock solutions were prepared in saline solution with 0.1% dimethylsulfoxide.
3.7.2. Cell Culture
MiaPaCa-2 pancreatic cancer cell lines were used throughout the study. Cells were grown in F-12
medium (Gibco, Grand Island, NY, USA) supplemented with 5% (v/v) fetal bovine serum (Gibco),
100 U/mL sodium penicillin G and 100 µg/mL streptomycin, and were maintained at 37 ◦C in a
humidified atmosphere containing 5% CO2. The compounds used in cell incubations were dissolved
in dimethylsulfoxide (DMSO) and the final concentration of DMSO in the medium was always kept
lower than 1% (v/v) [50].
3.7.3. Cell Viability Studies
Thirty thousand MiaPaca-2 cells were seeded in 35 mm diameter dishes with 2 mL of F-12 medium.
Cells were cultured for 2 h without treatment and then incubated with different compounds at the
indicated concentrations. After 7 days of incubation, cell growth was determined by the MTT test.
Briefly, 200 µL of a 0.5 mg/mL MTT solution [3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium
bromide] (Sigma-Aldrich, Barcelona, Spain) and 700 µL of a 50 mM succinic acid solution, both in PBS,
were added to each well. The plates were incubated at 37 ◦C for 3 h to allow the formation of formazan
crystals. Then, the dark blue crystals were dissolved with 10% sodium dodecyl sulfate (SDS) in DMSO
solution and their absorbance was read at 570 nm in a spectrophotometer. Results are expressed as a
percentage of viability with respect to the control cells grown in the absence of compounds [51].
3.8. Data Analysis
All experiments were carried out in triplicate. The results were analyzed and expressed as mean
± standard deviation (SD). Statistical analysis was done using one-way analysis of variance.
4. Conclusions
Four derivatives 1a, 1b, 1c and 1d were prepared from natural flavanone 1 by a molecular design
strategy (pharmacomodulation); two if these compounds (1a and 1c) are novel compounds, and they
have not been reported yet in the literature. All compounds belong to the group of flavonoids with
potential importance in human health. Prenylated flavanones have an important role as potential
chemotherapeutic agents. The development of semi-synthetic methodology towards the novel pyrano
system of prenyl flavanones will allow the investigation of related natural productbased heterocycles
of this kind of compounds. Particularly, derivative 1b can be proposed applications. For this task
biopharmaceutical studies should be accomplished.
PLGA NPs were prepared using the solvent displacement technique. The morphology, Z-average
and ZP characterization demonstrated that PLGA NPs were within acceptable parameters, showing
small, homogeneous and negatively charged NPs. Concretely, NPs loading derivatives 1a and 1b were
the nano-structured formulation showing the best results against MiaPaca-2 cell line, probably due
to the increment of the lipophilicity provided by an acetyl moiety and methyl group, respectively.
These might also be proposed as candidates for additional research to investigate their potential
medical applications.
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